Atrogi's 'Exercise Pill' Enters Trial, Aiming to Reshape Metabolic Disease Treatment

STOCKHOLM – March 18, 2026 – Swedish biotech firm Atrogi AB has initiated a new human trial for its lead drug candidate, ATR-258, an innovative oral therapy designed to mimic the benefits of physical exercise. The announcement marks a pivotal step for a drug that promises to not only induce fat loss and improve metabolism but also, crucially, build and preserve muscle mass—addressing a major drawback of current blockbuster weight-loss medications.

The first subjects have been dosed in an 8-week study that will scrutinize the drug's physiological effects on the muscles of overweight male volunteers. This development moves the so-called 'exercise pill' from a tantalizing concept closer to a potential clinical reality, with broad implications for treating obesity, type 2 diabetes, and age-related muscle wasting.

A New Frontier in Metabolic Health

At the heart of Atrogi's innovation is ATR-258, a first-in-class oral therapy that selectively targets the β2-adrenergic receptor (β2-AR) in skeletal muscle. For decades, scientists have known that activating this receptor can stimulate muscle growth and metabolism. However, earlier attempts to harness this pathway with drugs known as β2-agonists were thwarted by dangerous cardiovascular side effects, limiting their use to short-term applications like asthma inhalers.

Atrogi claims to have solved this long-standing problem. Its breakthrough, detailed in a landmark Cell paper in June 2025, lies in a highly specific mechanism called 'biased signaling.' ATR-258 is designed to activate only the beneficial downstream pathways within muscle cells responsible for growth and energy uptake, while avoiding the pathways that lead to adverse cardiac events like increased heart rate.

"This trial will allow us to rigorously interrogate targeted downstream effector signaling associated with the β2-adrenergic receptor in human skeletal muscle using a highly selective next generation modulator," said Morten Hostrup, Associate Professor at the University of Copenhagen and the study's Principal Investigator. He added that the goal is to understand how this signaling can be "harnessed to preserve, or even augment, muscle function in various conditions of muscle wasting."

Professor Tore Bengtsson, Atrogi's Founder and Chief Scientific Officer, whose decades of research underpin the technology, expressed his excitement about the collaboration. "Professor Hostrup is widely recognised as the leading expert in the field... His decision to sponsor this study speaks to the strength of our science and technology, and we look forward to sharing the results later this year."

The Race to Preserve Muscle in the Age of GLP-1s

Atrogi's announcement comes at a critical time in the pharmaceutical industry. The market for metabolic disease is currently dominated by GLP-1 receptor agonists like Ozempic and Wegovy, which have revolutionized obesity treatment with their potent weight-loss effects. However, this success has exposed a significant weakness: patients on these drugs often lose a substantial amount of lean muscle mass along with fat, sometimes as much as 40% of their total weight loss. This is particularly concerning for older adults, who are already at risk of sarcopenia, a progressive loss of muscle that can lead to frailty and disability.

This 'muscle problem' has ignited a new biotech race to develop therapies that can be paired with or offered as an alternative to GLP-1s, specifically to preserve or build muscle. Competitors are exploring various mechanisms, from inhibiting proteins that limit muscle growth to developing new hormone combinations.

Atrogi's ATR-258 enters this race with a unique proposition. Instead of merely acting as a defensive add-on, it offers a proactive, multi-pronged attack on metabolic disease by simultaneously promoting fat metabolism, improving glucose uptake, and actively building lean mass—the very definition of an 'exercise-mimetic.' If successful, it could offer a more holistic treatment, ensuring that weight loss is healthy and sustainable.

From Lab Bench to Human Trials

The current study builds on a strong foundation of preclinical and early-stage clinical data. The 2025 Cell paper also detailed results from a 69-subject Phase 1 trial, which demonstrated that ATR-258 was safe and well-tolerated in both healthy volunteers and patients with type 2 diabetes. That initial trial established a critical safety profile, particularly regarding the cardiovascular system, paving the way for further investigation.

The new 8-week trial, led by Professor Hostrup, is designed to generate key data on the drug's direct impact on muscle physiology. By combining detailed muscle measurements with advanced molecular analysis in human subjects, the study aims to provide definitive proof of the drug's mechanism of action in the body. This data will be crucial for designing larger, pivotal Phase 2 trials.

"The initiation of this study, and dosing of the first subjects, marks an important milestone for Atrogi," commented Paul Little, Chief Executive Officer at Atrogi. "With safety established in Phase 1 and a validated mechanism of action, the generation of key muscle physiology data from this trial will underpin ATR-258's further development across metabolic and muscle-wasting conditions."

With a well-defined scientific rationale and a clear clinical path, Atrogi is positioning itself as a key innovator in a rapidly evolving field. The results from the current trial, expected later in 2026, will be closely watched by investors, pharmaceutical giants, and a public eager for safer and more effective solutions to the twin epidemics of obesity and diabetes.